Sanofi India Limited reported a robust second quarter of fiscal year 2026 (Q2FY26), with profit before tax rising 19% year-on-year to ₹1,123 million. The pharmaceutical company’s domestic net sales grew by 8% to ₹4,377 million, while total net sales increased by 6% compared to the same period last year. This performance underscores the company's strong market position in the diabetes care segment, where its insulin portfolio delivered double-digit growth for the second consecutive quarter.

The Board of Directors approved the unaudited financial results on August 04, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by Price Waterhouse & Co Chartered Accountants LLP, the statutory auditors, who issued a limited review report confirming compliance with applicable accounting standards.

Key Financial Metrics

Profit before tax as a percentage of net sales improved to 27% in Q2FY26, up from 24% in Q2FY25. This margin expansion was driven by a favorable product mix and disciplined cost management. Operating expenses, comprising employee costs and other expenses, declined by 5% compared to the second quarter of 2025.

Segment Performance

The insulin portfolio continued its strong trajectory, delivering 14% growth. Sanofi maintains a leadership position in the basal analog market with a 58% value market share and 61% volume market share. Growth was powered by key brands including Lantus®, Toujeo®, and Apidra®, alongside the successful performance of Soliqua®.

The public sector business accelerated significantly, growing by 70%. This surge was attributed to the opening of new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, strengthening the company's footprint in the diabetes injectable space. Partnership revenues in Cardiovascular, Oral anti-Diabetes, and Central Nervous System segments grew by 2%, while export sales remained broadly stable amid global headwinds.

What the Numbers Show

A notable divergence exists between operating profit growth and working capital movements. While operating expenses declined by 5%, trade receivables surged from ₹1,767 million at the end of FY25 to ₹2,321 million at the end of Q1FY26, an increase of ₹554 million. This suggests potential collection pressure or extended credit terms in the distribution channel, even as cash and cash equivalents rose to ₹3,590 million. The company generated ₹2,114 million in net cash inflow from operating activities during the half-year ended June 30, 2026, down from ₹2,910 million in the same period last year, primarily due to changes in working capital dynamics.

Corporate Governance Updates

The Board also reconstituted two key committees effective October 01, 2026:

• Stakeholders Relationship Committee: Chaired by Independent Director Siraj Chaudhry, with Managing Director Deepak Arora and Whole Time Director Sudipta Chakraborty as members.
• Risk Management Committee: Chaired by Independent Director Rajani Kesari, with members Siraj Chaudhry, Deepak Arora, and Whole Time Director Mahadev Gawade.

Additionally, Rachid Ayari will step down as Whole Time Director and Chief Financial Officer on September 30, 2026. His name will be removed from the list of Key Managerial Personnel authorized to make disclosures to stock exchanges.

Sanofi announced on August 4, 2026, that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age. This regulatory milestone expands the vaccine’s reach to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Previously, MenQuadfi was approved in the European Union for use in individuals aged 12 months and older. The expanded indication addresses a critical public health need, as infants face high rates of mortality and severe long-term complications from the disease, which can progress from onset to death within 24 hours.

The approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use on June 25, 2026. It marks the completion of all pediatric post-licensure commitments linked to MenQuadfi’s initial marketing authorization, confirmed by the receipt of a Paediatric Investigation Plan compliance statement from the European Medicines Agency. This regulatory clearance provides healthcare professionals in the EU with an additional option for vaccinating infants against invasive meningococcal disease from as early as six weeks of age, aligning with routine infant immunization schedules.

Clinical Data and Safety Profile

The EU approval is underpinned by comprehensive data from the MET58 pivotal clinical study, which evaluated the immunogenicity, safety, and tolerability of MenQuadfi in infants from six weeks of age. The study included more than 6,000 infants across 11 countries and multiple immunization schedules. Federico Martinon-Torres, Pediatrician and Clinical Researcher at Hospital Clínico Universitario de Santiago in Spain and Principal Investigator of MET58, noted that the immunogenicity data for MenQuadfi in infants is robust and supports usage with confidence in the EU.

MenQuadfi demonstrates a safety profile comparable to other MenACWY vaccines currently licensed. In infants, the vaccine can be co-administered with combined diphtheria-tetanus-acellular pertussis (DTaP)-inactivated poliovirus (IPV)-hepatitis B (HepB)-Haemophilus influenzae type b (Hib) vaccine, rotavirus vaccine (live attenuated), and 10-valent pneumococcal conjugate vaccine (PCV10).

Approved Dosing Regimens

The new dose regimen for those starting vaccination from six weeks of age is aligned with standard EU immunization schedules. The approved dosing protocols are detailed below:

Public Health Impact

Invasive meningococcal disease carries a case fatality rate of approximately 10–15%, with up to 20% of survivors experiencing permanent complications such as limb amputation, hearing loss, and neurological damage. Although serogroup A is rarely reported in the EU, serogroups C, W, and Y remain responsible for a significant share of cases across Europe. Bogdana Coudsy, Global Head of Medical, Vaccines at Sanofi, stated that offering protection for the EU’s youngest children reflects the scientific rigor behind the work and provides healthcare providers with an additional option to protect infants from the early weeks of life. MenQuadfi is currently approved in the EU, US, and multiple other countries.